Inside the Pipeline: TRI-611 and ALK-positive Treatment Strategies
In this ALKtALK, we’re joined by Alexander Spira, MD, PhD, FASCO, medical oncologist at Virginia Cancer Specialists and member of the ALK Positive Scientific Advisory Board. Dr. Spira shares insights and expertise on two clinical trials for ALK-positive patients—TRI-611 and Gilteritinib—and what they may mean for the ALK-positive community. Drawing on his experience as a leading thoracic oncologist involved in advancing clinical research and treatment strategies, he offers valuable perspective on the evolving landscape of ALK+ care. This conversation also includes a community Q&A, with thoughtful questions from patients and care partners. ALKtALKs bring our community together with leading experts so patients and care partners can stay informed and empowered through shared knowledge and conversation. ▶️ Watch now to learn more about emerging ALK+ clinical trials and what’s on the horizon. + + About our ALKtALKs and ALK Positive Inc + + + ALK Positive does not endorse specific treatments and does not provide medical advice. Questions and concerns should be raised with individual care teams. ALK Positive is a 501(c)(3)-registered, patient-driven organization that seeks a cure for ALK+ cancer and works to improve patients’ quality of life and life expectancy worldwide. ALK Positive is committed to raising funds for research proposals that will transform ALK-positive cancer into a chronic or curable condition for all patients living with this disease. We offer a full range of Healing Arts classes to help our community balance a productive life, treatment side effects and the mental stress of a cancer diagnosis. These include ALKtALKs -- our flagship community program aimed at making our ALK community a little smarter and a little smaller, by bringing the latest information, research and practices from leading experts. For more information about us, go to www.alkpositive.org. To donate 💖 go to https://www.alkpositive.org/ways-to-give 📢 Follow us on social media & join the conversation online! Facebook 📘 / alkpositivecancer Instagram 📸 / alkpositiveinc LinkedIn 💼 / alkpositivecancer X (Twitter) ✖️ https://x.com/ALKPositiveinc TikTok 🎵 / alkpositiveinc BlueSky ☁️ https://bsky.app/profile/alkpositive....

Fueling the Breakthrough: ALK Positive Research and Medical Committee Update with Dr. Ken Culver

Navigating Brain Progression in ALK-positive Cancer: TKIs, Radiation, LMD, and More

UNC Bronchiectasis/NTM Care and Research Center World Bronchiectasis Day Celebration

Clinical Trials Connect: Session 2 | ALK+ Trial Tools & Q&A with Ellee Urban

What are Biomarkers and Why Should You Get Tested?

Dr. Christine Lovly Joins ALKtALK from the American Society of Clinical Oncology

Navigating ALK-positive Clinical Trials: Facts, Timelines & Real Expectations

FAQs: Immunotherapy for Multiple Myeloma: Exploring Options Through Your Disease Journey

Advancing Research Elevating Hope: A Conversation with Dr. Alice Shaw

Brian Cox- The Fermi Paradox Will Change How You See The Universe

Your Multiple Myeloma Lab Results, Decoded: What They Mean and What They Don’t

AI Is Creating A Rare Opportunity For Investors. How Jim Roppel Is Playing It. | Investing With IBD

July 7, 2026 Tuesday Notary Titans (TNT)! 🧨

Dr Sydney Barned on side effects when acceptable becomes unacceptable

Rethinking Aging in Place: Smart Homes, Wellness & Better Living

New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-Positive Cancer

Clinical Trials Connect

Jesse Boehm Returns to ALKtALK: A discussion on what’s next for the PowerRD 2 Cure ALK+ Lung TeamLab

Friday Night Lights | Next Legacy Group 7-10-2026

